AtaiBeckley reports Q4/FY2025: net loss $660M; BPL-003 Phase 3 on track for Q2 2026

AtaiBeckley Inc.

Cash $220.7M as of Dec 31, 2025; runway to early 2029 topline readouts.
Net loss $544.8M in Q4, $660M full year; includes $530M non-cash IP R&D charge from Beckley Psytech combo.
BPL-003 Phase 3 pivotal program (ReConnection-1 and -2) initiation on track for Q2 2026; topline data early 2029.
EMP-01 Phase 2a met primary safety; showed 11.85-point LSAS reduction vs placebo (p=0.036).
VLS-01 Phase 2 Elumina topline data readout anticipated H2 2026.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

AtaiBeckley Inc. reported financial results for fourth quarter and year ended December 31, 2025.

Period: fourth quarter and year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 6, 2026, AtaiBeckley Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025 and provided a corporate and clinical update.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

AtaiBeckley Inc. filing history →

Source: SEC EDGAR

accession 0001140361-26-008178

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.